Trial Profile
A Phase III Randomized, Double-blinded Trial of Platinum-based Chemotherapy With or Without Atezolizumab Followed by Niraparib Maintenance With or Without Atezolizumab in Patients With Recurrent Ovarian, Tubal or Peritoneal Cancer and Platinum Treatment-free Interval (TFIp) >6 Months
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Jan 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin (Primary) ; Doxorubicin liposomal (Primary) ; Gemcitabine (Primary) ; Niraparib (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms ANITA
- 24 Oct 2023 Primary analysis results ( at the data cut-off 15 Apr 2023, n=417) presented at the 48th European Society for Medical Oncology Congress.
- 11 Sep 2023 Planned End Date changed from 1 Jan 2025 to 1 Jan 2024.
- 11 Sep 2023 Planned primary completion date changed from 1 Aug 2024 to 1 Jan 2024.